Noordhoek I, Blok EJ, Meershoek-Klein Kranenbarg E, Putter H, Duijm-De Carpentier M, Rutgers EJT, et al. Overestimation of late distant recurrences in high-risk patients with ER-positive breast cancer: validity and accuracy of the CTS5 risk score in the TEAM and IDEAL trials. J Clin Oncol. 2020;38(28):3273–81.
Article
Google Scholar
Richman J, Dowsett M. Beyond 5 years: enduring risk of recurrence in oestrogen receptor-positive breast cancer. Nat Rev Clin Oncol. 2019;16(5):296–311.
Article
CAS
Google Scholar
Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381(9869):805–16.
Article
CAS
Google Scholar
Mamounas EP, Bandos H, Lembersky BC, Jeong JH, Geyer CE, Rastogi P, et al. Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(1):88–99.
Article
CAS
Google Scholar
Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005;97(17):1262–71.
Article
CAS
Google Scholar
Abe O, Abe R, Enomoto K, Kikuchi K, Koyama H, Masuda H, et al. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687–717.
Article
Google Scholar
Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P, et al. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med. 2017;377(19):1836–46.
Article
Google Scholar
Szostakowska M, Trębińska-Stryjewska A, Grzybowska EA, Fabisiewicz A. Resistance to endocrine therapy in breast cancer: molecular mechanisms and future goals. Breast Cancer Res Treat. 2019;173(3):489.
Article
Google Scholar
Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL, et al. Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update. J Clin Oncol. 2020;38(12):1346–66.
Article
Google Scholar
Huang L, Liang G, Zhang Q, Zhao W. The role of long noncoding rnas in antiestrogen resistance in breast cancer: an overview and update. J Breast Cancer. 2020;23(2):129.
Article
Google Scholar
Wang X, Wang S. Identification of key genes involved in tamoxifen-resistant breast cancer using bioinformatics analysis. Transl Cancer Res. 2021;10(12):5246.
Article
CAS
Google Scholar
Dowsett M, Allred C, Knox J, Quinn E, Salter J, Wale C, et al. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the arimidex, tamoxifen, alone or in combination trial. J Clin Oncol. 2008;26(7):1059–65.
Article
CAS
Google Scholar
Viale G, Regan MM, Maiorano E, Mastropasqua MG, Dell’Orto P, Rasmussen BB, et al. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol. 2007;25(25):3846–52.
Article
Google Scholar
Bartlett JMS, Brookes CL, Robson T, Van De Velde CJH, Billingham LJ, Campbell FM, et al. Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the tamoxifen and exemestane adjuvant multinational trial. J Clin Oncol. 2011;29(12):1531–8.
Article
CAS
Google Scholar
Hon JDC, Singh B, Sahin A, Du G, Wang J, Wang VY, et al. Breast cancer molecular subtypes: from TNBC to QNBC. Am J Cancer Res. 2016;6(9):1864–72.
CAS
Google Scholar
Bronte G, Rocca A, Ravaioli S, Puccetti M, Tumedei MM, Scarpi E, et al. Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy? BMC Cancer. 2018;18(1):1–8.
Article
Google Scholar
Elebro K, Borgquist S, Simonsson M, Markkula A, Jirström K, Ingvar C, et al. Combined androgen and estrogen receptor status in breast cancer: treatment prediction and prognosis in a population-based prospective cohort. Clin Cancer Res. 2015;21(16):3640–50.
Article
CAS
Google Scholar
Hilborn E, Gacic J, Fornander T, Nordenskjöld B, Stål O, Jansson A. Androgen receptor expression predicts beneficial tamoxifen response in oestrogen receptor-α-negative breast cancer. Br J Cancer. 2016;114(3):248.
Article
CAS
Google Scholar
Cochrane DR, Bernales S, Jacobsen BM, Cittelly DM, Howe EN, D’Amato NC, et al. Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide. Breast Cancer Res. 2014;16(1):R7.
Article
Google Scholar
Cao L, Xiang G, Liu F, Xu C, Liu J, Meng Q, et al. A high AR:ERα or PDEF:ERα ratio predicts a sub-optimal response to tamoxifen therapy in ERα-positive breast cancer. Cancer Chemother Pharmacol. 2019;84(3):609–20.
Article
CAS
Google Scholar
Kamranzadeh H, Ardekani RM, Kasaeian A, Sadighi S, Maghsudi S, Jahanzad I, et al. Association between Ki-67 expression and clinicopathological features in prognosis of breast cancer: a retrospective cohort study. J Res Med Sci. 2019;24(1).
Liang Q, Ma D, Gao RF, Da YuK. Effect of Ki-67 expression levels and histological grade on breast cancer early relapse in patients with different immunohistochemical-based subtypes. Sci Rep. 2020;10(1):1–9.
Google Scholar
Zhang Y, Schnabel CA, Schroeder BE, Jerevall PLL, Jankowitz RC, Fornander T, et al. Breast cancer index identifies early-stage estrogen receptor-positive breast cancer patients at risk for early- and late-distant recurrence. Clin Cancer Res. 2013;19(15):4196–205.
Article
CAS
Google Scholar
Bartlett JMS, Sgroi DC, Treuner K, Zhang Y, Ahmed I, Piper T, et al. Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the adjuvant tamoxifen—to offer more? (aTTom) trial. Ann Oncol. 2019;30(11):1776–83.
Article
CAS
Google Scholar
Noordhoek I, Treuner K, Putter H, Zhang Y, Wong J, Kranenbarg EMK, et al. Breast cancer index predicts extended endocrine benefit to individualize selection of patients with HRþ early-stage breast cancer for 10 years of endocrine therapy. Clin Cancer Res. 2021;27(1):311–9.
Article
CAS
Google Scholar
Sgroi DC, Carney E, Zarrella E, Steffel L, Binns SN, Finkelstein DM, et al. Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13/IL17BR biomarker. J Natl Cancer Inst. 2013;105(14):1036–42.
Article
CAS
Google Scholar
Gray RG, Rea D, Handley K, Bowden SJ, Perry P, Earl HM, et al. aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6953 women with early breast cancer. J Clin Oncol. 2013;31(5):5.
Article
Google Scholar
Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999;17:1474–81.
Article
CAS
Google Scholar
Nielsen TO, Leung SCY, Rimm DL, Dodson A, Acs B, Badve S, et al. Assessment of Ki67 in breast cancer: updated recommendations from the international Ki67 in Breast Cancer Working Group. J Natl Cancer Inst. 2021;113(7):808–19.
Article
Google Scholar
Ma XJJ, Hilsenbeck SG, Wang W, Ding L, Sgroi DC, Bender RA, et al. The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer. J Clin Oncol. 2006;24(28):4611–9.
Article
CAS
Google Scholar
Bartlett JMS, Sgroi DC, Treuner K, Zhang Y, Piper T, Salunga RC, et al. Breast Cancer Index is a predictive biomarker of treatment benefit and outcome from extended tamoxifen therapy: final analysis of the Trans-aTTom study. Clin Cancer Res. 2022;3385
Treuner K, Hayes M, Benner C, Schnabel C, Heinz S. Abstract P6-04-17: role of HOXB13 in modulating estrogen signaling in breast cancer cells. In: Cancer Research. American Association for Cancer Research (AACR); 2020. p. P6-04-17.
Kim C, Tang G, Pogue-Geile KL, Costantino JP, Baehner FL, Baker J, et al. Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer. J Clin Oncol. 2011;29(31):4160–7.
Article
CAS
Google Scholar
Mamounas EP, Bandos H, Rastogi P, Zhang Y, Treuner K, Lucas PC, et al. Breast Cancer Index (BCI) and prediction of benefit from extended aromatase inhibitor (AI) therapy (tx) in HR+ breast cancer: NRG oncology/NSABP B-42. J Clin Oncol. 2021;42:501.
Article
Google Scholar
Fu X, Pereira R, de Angelis C, Veeraraghavan J, Nanda S, Qin L, et al. FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer. Proc Natl Acad Sci U S A. 2019;116(52):26823–34.
Article
CAS
Google Scholar
Theodorou V, Stark R, Menon S, Carroll JS. GATA3 acts upstream of FOXA1 in mediating ESR1 binding by shaping enhancer accessibility. Genome Res. 2013;23(1):12–22.
Article
CAS
Google Scholar
Fortelny N, Overall CM, Pavlidis P, Freue GVC. Can we predict protein from mRNA levels? Nature. 2017;547(7664):19–20.
Article
Google Scholar
Lundin KB, Henningson M, Hietala M, Ingvar C, Rose C, Jernström H. Androgen receptor genotypes predict response to endocrine treatment in breast cancer patients. Br J Cancer. 2011;105(11):1676.
Article
CAS
Google Scholar
Masuda H, Masuda N, Kodama Y, Ogawa M, Karita M, Yamamura J, et al. Predictive factors for the effectiveness of neoadjuvant chemotherapy and prognosis in triple-negative breast cancer patients. Cancer Chemother Pharmacol. 2011;67(4):911–7.
Article
CAS
Google Scholar
Rangel N, Rondon-Lagos M, Annaratone L, Felipe Aristizábal-Pachon A, Cassoni P, Sapino A, et al. AR/ER ratio correlates with expression of proliferation markers and with distinct subset of breast tumors. Cells. 2020;9(4):1064.
Article
CAS
Google Scholar
Harbeck N, Rastogi P, Martin M, Tolaney SM, Shao ZM, Fasching PA, et al. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study. Ann Oncol. 2021;32(12):1571–81.
Article
CAS
Google Scholar
Camp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab Invest. 2000;80(12):1943–9.
Article
CAS
Google Scholar
Krauss K, Stickeler E. Endocrine therapy in early breast cancer. Breast Care (Basel). 2020;15(4):337–46.
Article
Google Scholar
Bago-Horvath Z, Rudas M, Dubsky P, Jakesz R, Singer CF, Kemmerling R, et al. Adjuvant sequencing of tamoxifen and anastrozole is superior to tamoxifen alone in postmenopausal women with low proliferating breast cancer. Clin Cancer Res. 2011;17(24):7828–34.
Article
CAS
Google Scholar
Viale G, Giobbie-Hurder A, Regan MM, Coates AS, Mastropasqua MG, Dell’Orto P, et al. Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from breast international group trial 1–98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol. 2008;26(34):5569.
Article
Google Scholar
Regan MM, Pagani O, Francis PA, Fleming GF, Walley BA, Kammler R, et al. Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials. Breast Cancer Res Treat. 2015;154(2):275–86.
Article
CAS
Google Scholar
Beelen K, Opdam M, Severson T, Koornstra R, Vincent A, Wesseling J, et al. Mitotic count can predict tamoxifen benefit in postmenopausal breast cancer patients while Ki67 score cannot. BMC Cancer. 2018;18(1):1–11.
Article
Google Scholar
Watanabe T, Oba T, Tanimoto K, Shibata T, Kamijo S, Ito KI. Tamoxifen resistance alters sensitivity to 5-fluorouracil in a subset of estrogen receptor-positive breast cancer. PLoS ONE. 2021;16:e0252822.
Article
CAS
Google Scholar
NCCN Clinical Practice Guidelines in Oncology. Breast cancer, version 2.2022. National Comprehensive Cancer Network. 2022.
Andre F, Ismaila N, Allison KH, Barlow WE, Collyar DE, Damodaran S, et al. Biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer: ASCO guideline update. J Clin Oncol. 2022;40:1816–37.
Article
CAS
Google Scholar